TWD 36.25
(-0.14%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -57.55 Million TWD | -1014.89% |
2022 | 6.29 Million TWD | -83.62% |
2021 | 38.4 Million TWD | -44.4% |
2020 | 69.07 Million TWD | 226.79% |
2019 | -54.47 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -81.36 Million TWD | -41.37% |
2024 Q2 | -72.39 Million TWD | 11.03% |
2023 Q2 | -12.62 Million TWD | -168.89% |
2023 FY | -57.55 Million TWD | -1014.89% |
2023 Q1 | 18.32 Million TWD | 474.48% |
2023 Q4 | -57.55 Million TWD | -81.7% |
2023 Q3 | -31.67 Million TWD | -150.91% |
2022 Q4 | -4.89 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 132.314% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 280.279% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 146.628% |
TTY Biopharm Company Limited | -705.97 Million TWD | 91.847% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 103.783% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 101.853% |
Center Laboratories, Inc. | 3.91 Billion TWD | 101.469% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 109.084% |
InnoPharmax Inc. | -17.85 Million TWD | -222.298% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 93.79% |
Excelsior Biopharma Inc. | -212.51 Million TWD | 72.916% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 135.816% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 92.634% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 91.197% |
UniPharma Co., Ltd. | -68.36 Million TWD | 15.813% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 111.689% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 92.202% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | 69.993% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -2859.177% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -111.354% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | 89.88% |